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ISSNObjective: To facilitate collection of cumulative data on longitudinal HIV disease
outcomes during HIV prevention studies by developing recommendations for follow-up
of the relatively few study participants with breakthrough infections.
Design: We formed a working group to compare and contrast the various approaches
taken in recent HIV prevention trials, to summarize the advantages and disadvantages
associated with each, and to explore the feasibility of developing protocols for the long-
term follow-up of seroconverters.
Methods: We reviewed study designs, objectives, and assessments in 15 interventional
studies that followed HIV seroconverters. Protocol team members joined discussions of
the various approaches and developed recommendations.
Results: Most HIV prevention clinical trials share a core set of objectives, including the
description/comparison of virological, immunological, and clinical course of HIV, and
sometimes a comparison of preseroconversion and postseroconversion behavior. Long-
term follow-up of seroconverters can be conducted in separate studies if the transition
from parent protocol is effectively managed.
Conclusion: We recommend the development of harmonized seroconverter protocols.
Although specific research questions in the postseroconversion period may differ
depending on prevention modality, harmonizing key evaluations would create an
opportunity to ask overarching questions that inform the prevention field with respect to
design and implementation of future combination prevention studies. Follow-up
immediately postseroconversion should be conducted in the parent protocol before
roll over into a follow-up protocol. Development of specimen repositories with ample
volumes for future assays, standardized definitions of infection, diagnosis and sero-
conversion dates, and harmonization of study objectives and sample collections at key
time points are important.  2013 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2013, 27:1119–1128Keywords: clinical trials as topic, HIV, HIV seroconversion,
pathogenesis, preventionippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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The natural history of HIV infection has been an area of
intense study since the start of the epidemic. Initially, and
throughout the epidemic, HIV-1 seroconverters were
followed longitudinally to describe the clinical, viro-
logical, and immunological trajectory of treated [1,2] and
untreated HIV disease [3–6] and transmission [7]. Early
studies also focused on psychosocial and behavioral
factors associated with HIV transmission and infection
[8,9]. Long-term follow-up of HIV-infected individuals
in natural history studies sheds light on issues such as host
genetic factors of resistance and long-term nonprogres-
sion [10,11], the impact of treatment on disease
progression [12], HIV-1 transmission during and after
seroconversion [13], and the effects of a positive test on
sexual risk behavior [14]. Some groups followed
seroconverters within the context of breakthrough
infection studies conducted in high-risk populations
not exposed to biomedical preventions to meet a variety
of study objectives [15–18], and pathogenesis work
during acute infection and long-term follow-up has
elucidated the concept of ‘founder viruses’ in the
establishment of HIV infection [19,20].
As it became clear that CD4þ T-cell counts [21,22] and
plasma HIV RNA [22,23] during the first 6 months of
infection were strong predictors of disease progression [24],
the need for expensive long-term follow-up of serocon-
verters in HIV-1 prevention clinical trials was reduced for a
time. For example, the HIV Prevention Trials Network’s
HPTN 052, which showed that antiretroviral therapy
(ART) drastically reduces the sexual transmission of HIV in
heterosexual serodiscordant couples [25], did not follow
seroconverters after obtaining initial samples and assess-
ments. Also, behavioral prevention studies have not
typically needed long-term follow-up of seroconverters
to obtain study endpoints, which focused on the primary
endpoint – incident HIV infection [26,27].
More recently, however, vaccine and preexposure
prophylaxis (PrEP) studies have sought to understand
the effects of biomedical interventions on correlates of
disease progression [28,29]. In addition, as HIV-infected
individuals age, describing development of HIV-associ-
ated non-AIDS-related conditions in these cohorts of
seroconverters who received PrEP and/or a vaccine may
become important. Elucidating the correlations of HIV-
associated inflammation will also require longitudinal data
from seroconverters from diagnosis through ART.
Increasingly, answering these contemporary research
questions requires the short- and long-term follow-up
of study participants who become infected with HIV-
1[30], especially in phase 3 trials of partially effective
biomedical prevention modalities.
Some networks, such as the HIV Vaccine Trials Network
(HVTN) [31,32] and the Microbicide Trials Networkpyright © Lippincott Williams & Wilkins. Unautho(MTN) [33], have already developed studies for the long-
term study of participants who seroconverted while in
follow-up during late phase prevention trials. However,
harmonization of study protocols that follow serocon-
verters in such a way that would allow for cross-study
analysis remains a challenge. Depending on the nature of
the study question, standardizing follow-up, and collec-
tion of data at key postinfection time points may yield
increased statistical power, but more importantly it would
create an opportunity to ask overarching questions
about the course of HIV infection in individuals who
participated in prevention trials, such as development of
drug resistance, change in risk behavior, secondary
transmission, and development of non-AIDS-related
complications. The ability to ask these questions in a
systematic fashion will inform design of future interven-
tion studies and demonstration projects. We therefore
conducted a comparative analysis of recent or current
HIV biomedical prevention studies to answer the
questions: How can retention of participants who acquire
HIV in a prevention study and enroll in a seroconverter
study be maximized; What study objectives can and
should be answered by the short-term and long-term
follow-up of seroconverters; and, Which biological
specimens and assessments can and should be recom-
mended for all studies that follow seroconverters.Methods
The leaders of the National Institutes of Health (NIH)-
funded HIV/AIDS clinical trials networks requested that
the Office of HIV/AIDS Network Coordination
(HANC) convene senior representatives of study teams
of network prevention studies that follow seroconverters
[31–38] to compare and contrast consent and retention
approaches, objectives, evaluations, and sample collec-
tions, and to prepare recommendations. The Serocon-
verter Study Group (SSG), comprised eight members,
held a total of nine teleconference discussions during
which the protocols were reviewed and recommen-
dations were developed. Non-network prevention studies
were also considered and senior representatives of these
protocols were invited to join group discussions on an ad
hoc basis [39–43].Results
Study design and operational details
A total of 15 studies that follow seroconverters were
reviewed and compared. Table 1 provides an overview of
these studies and Table 2 compares the aspects of study
design that pertain to seroconversion. The studies
represented a wide variety of prevention modalities,
including microbicides, oral PrEP, and vaccines in phase 1rized reproduction of this article is prohibited.
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CAPRISA 004 18–40 WSM ZA 889 May 2007 Concluded 30; avg. 18
TRAPS 18–40 WSM ZA 98 November 2007 Ongoing n/a
MTN-003 18–45 WSM Sub-Saharan Africa 5000 August 2009 Closed to accrual 14–38
MTN-015 Varies WSM MW, UG, ZA, ZM, ZW 500 August 2008 Enrolling n/a
Oral PrEP
studies
FEM-PrEP 18–35 WSM KE, TZ, ZA, MW, ZM 3900 May 2009 Closed to Follow-Up 14
FEM-PrEP Sxr
Substudy
18–35 WSM KE, TZ, ZA, MW, ZM 55 May 2009 Closed to follow-up n/a
HPTN 067 18 WSM, MSM TH, ZA 360 August 2011 Enrolling 8.5
HPTN 069 18 MSM US 400 Pending Pending 11.5
iPrEx Varies MSM PE, EC, US, BR, TH, ZA 2499 July 2007 Closed to accrual 11–33
iPrEx OLE Varies MSM PE, EC, US, BR, TH, ZA 1500 June 2011 Closed to enrollment 19
Partners PrEP 18–65 HIV neg. partners
in discordant
couples
KE, UG 3900 October 2009 Closed to follow-up 25–37
Vaccine
studies
HVTN 403 Varies W, M BR, PE, US, ZA 54 April 2002 Closed to follow-up n/a
HVTN 404 Varies W, M HT, PE, US, ZA 80 July 2008 Enrolling n/a
HVTN 505 18–50 MSMa US 2200 May 2009 Enrolling 60
HVTN 802 Varies W, M DO, HT, PE, US, ZA 230 July 2008 Enrolling n/a
Seroconverter rollover studies are bolded. BR, Brazil; CAPRISA, Centre for the AIDS Programme of Research in South Africa; DO, Dominican Republic; EC, Ecuador;
FEM-PrEP, Preexposure Prophylaxis Trial for HIV Prevention among African Women; HT, Haiti; HVTN, HIV Vaccine Trials Network; iPrEx, Iniciativa Profilaxis
Preexposicion (Prexposure Prophylaxis Initiative); KE, Kenya; M, men; MTN, Microbicide Trials Network; MW, Malawi; n/a, not applicable; OLE, open-label extension;
PE, Peru; PrEP, preexposure prophylaxis; TRAPS, Tenofovir gel Research for Advancing Prevention Science; TZ, Tanzania; UG, Uganda; US, United States; W, women;
WSM, women who have sex with men; ZA, South Africa; ZM, Zambia; ZW, Zimbabwe.
aAd5 nAb negative, circumcised, also includes M ! F transgender.to 3 testing. Duration of follow-up postseroconversion
differs from study to study. In some cases, seroconverters
are followed for a limited time in the ‘parent’ study
(e.g., MTN-003) before or while being transferred to a
separate ‘rollover’ study that only follows seroconverters
(e.g., MTN-015); in other cases, the seroconverters are
followed entirely within the parent study [e.g. Iniciativa
Profilaxis Preexposicion (Prexposure Prophylaxis Initiat-
ive) iPrEx] (see Table 2).
Seroconverter rollover studies typically enroll serocon-
verters from the parent study as soon as possible after HIV
diagnosis. However, the timing is usually flexible to allow
for maximum enrollment. The duration of follow-up also
varies. Although perhaps for different reasons, both
vaccine and biomedical studies follow seroconverters after
ART initiation.
The method used to determine HIV diagnosis, infection,
or seroconversion (Table 2), and frequency of HIV testing
(Table 3) were compared across studies. Most studies
made use of a diagnosis date, although Preexposure
Prophylaxis Trial for HIV Prevention among African
Women (FEM-PrEP) estimated infection date and
Centre for the AIDS Programme of Research in South
Africa (CAPRISA 004) estimated seroconversion date.
Objectives
We compared the objectives for each study (Table 4).
Some interpretation and generalization was necessary to
develop a meaningful comparison. The most common
objectives, which were to describe/compare the vir-
ological, immunological, and clinical course of diseaseCopyright © Lippincott Williams & Wilkins. Unautand to assess drug resistance, are shown in Table 4 along
with three other objectives pertaining to behavioral
outcomes, evaluation of response to ART and develop-
ment of specimen repositories, which were less common
but of particular interest to the SSG. There were also a
variety of virological, immunological, mutation/drug
resistance, and other objectives that were used in only one
or two studies; these additional objectives typically related
to the intervention type (see Supplemental Digital
Content 1 and 2, http://links.lww.com/QAD/A297,
detailed objectives of each protocol).
Assessments and samples
Assessments and samples collected were reviewed for each
study (Table 3). Whole blood, serum/plasma, and
peripheral blood mononuclear cells (PBMC), at least
one type of genital or rectal secretion or biopsy, and urine
samples were commonly collected. Although few
protocols included study objectives specific to behavior,
most studies conducted ongoing behavioral assessments.
Only three studies included study objectives for devel-
opment of specimen repositories, but all studies collected
at least serum/plasma for storage.
The frequency and volume of blood draws varied across
protocols, but the trends were similar. Clinic visits and
blood draws are frequent in the weeks and months
following HIV diagnosis and become less frequent as time
passes. The most intense period of follow-up is typically
the first 3 months. See Supplemental Digital Content 3,
http://links.lww.com/QAD/A297 for more detailed
information about the frequency of HIV testing and visits.horized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Various organizations conducting HIV prevention trials
have been committed to following individuals who
seroconvert while enrolled in HIV prevention studies by
either incorporating 3–38 months of follow-up into the
parent study or offering enrollment in a separate
seroconverter rollover study. Such studies have enabled
evaluation of clinical, immunological, virological, drug
resistance, and other outcomes. A common protocol
design and/or common protocol, such as a network-
specific or cross-network seroconverter study for the
long-term follow-up of study participants who serocon-
vert while participating in a prevention study, can ease
aggregation of data. A common protocol design would
need to consider consent, retention, study objectives,
sample collections and assessments, and consistent
determination and use of diagnosis, estimated infection,
and/or estimated seroconversion dates. For advancing
the greater HIV prevention research agenda, early
negotiation of data sharing agreements among study
teams would be ideal.
Recommendations: study design and operational
details
An important consideration when planning to follow
seroconverters is to determine how long to follow them
within the context of the parent study and when to ask
them to enroll in a seroconverter rollover study. The
timing of transition into a rollover study impacts the
number of participants recruited and long-term reten-
tion. Increasing retention (i.e., the proportion of all
seroconverters in a parent study that roll over into the
seroconverter study) is crucial to obtain sufficient sample
size for comparative analysis. There are presently
insufficient data on retention because many parent
studies are ongoing and remain blinded, so it is premature
to recommend an optimal time point for transition from
parent to rollover studies. However, anecdotally, reten-
tion is higher and easier when seroconverters are followed
within the context of the parent study for some period of
time. Consent for remaining in an HIV prevention study
in the event of seroconversion can be obtained from all
participants at the beginning of the parent study, but
consent for enrollment in a long-term seroconverter
follow-up study must be obtained separately. Also,
follow-up visits specific to seroconverters can be coor-
dinated with regular study visits, making it more con-
venient for the participants and further promoting
retention.
Following seroconverters within the context of the parent
studies for a limited period also facilitates the capture of
critical early postdiagnosis time point data; early time
points, evaluations, and events may pertain to the
objectives of the parent study. The MTN-015 study
team reported that enrollment delays have occurred while
HIV diagnoses are confirmed. Therefore, the MTN andpyright © Lippincott Williams & Wilkins. Unauthoother groups incorporated collection of early postdiag-
nosis samples into the parent protocols. Another strategy
for increasing retention in both the parent study at the
time of HIV diagnosis and enrollment into a rollover
study is to have a dedicated team of counselors meet with
participants who are diagnosed with HIV infection, as was
done during the CAPRISA 004 study when participants
were asked to enroll in Tenofovir gel Research for
Advancing Prevention Science (TRAPS). HIV diagnosis
is a difficult and challenging time both for the participants
and the counselors/clinicians who work with them.
Counseling by a trained, dedicated team provides needed
support and encouragement to remain on-study.
Building short-term seroconverter follow-up into the
parent study promotes retention at the point of HIV
diagnosis, allows time for obtaining consent for the
rollover study, and facilitates collection of clinical data and
specimens during early postdiagnosis time points, but
long-term follow-up of seroconverters is costly and
difficult to budget. Enrolling seroconverters from
multiple parent studies into a single or a few seroconverter
rollover studies may be more efficient and logistically
feasible. On the basis of these considerations the SSG
makes the protocol development, implementation, and
timing recommendations in Table 5. When developing a
seroconverter rollover study and determining the optimal
point of enrollment transition, the desire to ensure
retention and capture early time points postdiagnosis has
to be weighed against any potential gain in efficiency and
cost savings of a rollover study.
Duration of follow-up postdiagnosis would need to vary
by necessity, depending on the objectives of the parent
and rollover studies. For example, questions regarding
acute infection and correlates of harm and protection
would require a short duration of follow-up, perhaps until
participants reach viral set point. Those studies looking at
disease progressions might follow participants until
initiation of treatment. Studies looking at response to
treatment or comorbidities such as chronic inflammation
would necessitate a longer duration of follow-up. To
mitigate the costs of an extended follow-up period, the
frequency of visits would decrease over time. Potentially,
novel and inexpensive point-of-care testing technologies
could be incorporated to save cost and decrease burden on
participants and clinics.
Recommendations: study objectives
The studies were compared to determine the common
study objectives that would require follow-up of
seroconverters, and to recommend a core set of these
objectives for inclusion in all protocols that follow
seroconverters (both parent and rollover studies).
Delineation of a core set of objectives would facilitate
protocol development and future cross-study analyses of
clinical and laboratory data. The SSG found there were a
few objectives that were common to many studies, andrized reproduction of this article is prohibited.
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Develop network-specific or cross-network seroconverter studies for the long-term follow-up of study
participants who seroconvert while participating in a network prevention study
Timing of enrollment into
seroconverter rollover studies
Follow seroconverters in the short-term with in the context of the parent study before
or concurrent with rollover into a seroconverter follow-up study
Obtain consent for short-term and long-term follow-up postseroconversion, including
the collection of samples for future genomic testing, at the time of enrollment
Study objectives Develop for all prevention trials and all seroconverter rollover studies a core set of
objectives; allow study teams to add study-specific objectives as necessary. These objectives
should include:
Describe/compare the virological, immunological, and clinical course of HIV disease among
seroconverters in active compared to control arm
Assess drug resistance
Compare changes in risk behavior pre and postseroconversion
Evaluate response to therapy




Standardize definition, determination, and use of diagnosis dates, estimated infection




Develop a core set of sample collections and assessments for all prevention trials and all seroconverter
rollover studies; allow study teams to add study-specific sample collections and assessments as necessary.
Examples might include:







HIV rapid test M – – –
Urine/pregnancy test (women only) M M Q S
Clinical assessment M M Q S
Behavioral assessment M M Q S
Blood for HIV RNA testing and storage Q M Q S
M, Monthly; Q, Quarterly; S, Semiannually; sxn, seroconversion.also identified some objectives that are currently included
in two to four studies, but whose inclusion in future
studies would be recommended (see Table 5).
The most common objectives shared across all protocols
were to describe and compare the virological, immuno-
logical, and clinical course of HIV disease among
seroconverters in active and placebo arms and to assess
drug resistance; these objectives are included in the core
set of recommended objectives. Although most studies
collect behavioral risk information, very few have
objectives related to behavioral risk. Although these
objectives are not common, they would be recommended
for inclusion in a core set of objectives. Similarly,
although development of a specimen repository is a
specific objective in only four studies, it is recommended
as one of the core objectives. An evaluation of response to
ART is also recommended, as selected drug resistance
(owing to oral or topical antiretroviral-based PrEP), or
disease progression modulation (via vaccine induction),
may impact the natural history of treated and untreated
disease. There were many objectives that were common
to only a small number of studies (one to three), but
would not be suitable for inclusion in a core set of
objectives. These objectives would be considered to be
study-specific, and are examples of objectives that a
protocol team might choose to include in addition to the
recommended core objectives as appropriate (see
Supplemental Digital Content 1 and 2, http://links.lww.
com/QAD/A297, detailed objectives of each protocol).
One might expect differences between vaccine and PrEP
(microbicide and oral) protocols, but many similaritiesCopyright © Lippincott Williams & Wilkins. Unautwere found, indicating that a core set of seroconverter-
related objectives could be used in vaccine and PrEP
studies. Furthermore, as uptake of oral PrEP increases and
vaccine or other biomedical prevention studies allow for
or provide PrEP, rollover studies that include participants
from vaccine studies may need to evaluate the effects of
PrEP on seroconversion and other postseroconversion
endpoints.
Recommendations: sample collections and
assessments
To facilitate analysis of clinical and laboratory data across
studies, the protocols were compared to determine the
common sample collections/assessments and to develop a
core set that would be recommended for inclusion in all
studies that follow seroconverters. We found that the
samples collected varied across protocols, but those
supporting the common objectives described above
(whole blood, serum/plasma, and PBMCs), urine for
pregnancy testing, and various genital secretions and/or
biopsies are collected for most studies (Table 4) and would
be recommended for inclusion in a core set of samples.
Behavioral assessments are collected in most studies both
before and after diagnosis, but will pose particular
challenges to cross-protocol analysis. The specific
behavioral assessments, time frame for reporting, method
of administration, and scales all vary across protocols,
impeding cross-protocol comparison. Although acknow-
ledging that no gold standard exists for behavioral
assessments, development of best practices would
facilitate both cross-protocol comparison and develop-
ment of future protocols.horized reproduction of this article is prohibited.
Co
1126 AIDS 2013, Vol 27 No 7Ideally, specimens (e.g. blood, cells, and genital
secretions) should be banked in ample volumes for
future assays. Although only three rollover protocols
(MTN-015, HVTN 403, and HVTN 404) have specific
study objectives for developing a repository of specimens
for future analysis, most of the protocols store samples for
future testing at the site or at a central repository. Most
commonly stored are serum/plasma and cryopreserved
PBMCs; collection and repository storage of these
samples is recommended. Acknowledging that storage
of such specimens is particularly costly and poses
additional challenges in international settings, such a
repository would be high-yield for answering both
current and future research questions, many of which may
be exploratory and/or not fully developed at the time of
protocol conduct. Collection and storage of other sample
types could be added to meet study-specific objectives.
Maximum blood draw volumes varied widely, ranging
from 20 to 250 ml. It is unclear what factors contributed
to this range, but reports from study teams suggested that
local restrictions, cultural norms, and ethical consider-
ations may be a limiting factor. It has been reported that
some African communities believe a loss of blood leads to
a loss of energy, immune function, and/or virility, or that
it might be used in magic [44–47]. Culturally sensitive
training for site staff and participants may be required to
support collection of blood in volumes sufficient for real-
time and future testing,
Some investigators report that there have been challenges
to obtaining open-ended approval for genomic studies
from national/local ethics committees, which may
require more specific analysis plans and details for future
testing than are typically needed for regulatory approval
at US domestic sites. Ideally, collection of genomic
information would be included in a core set of sample
collections/assessments, although regulatory require-
ments may prove to be challenging.
Standardized timing of sample collections/assessments in
various protocols must also be considered if meaningful
conclusions are to be drawn, especially for early infection
events. For follow-up schedules and analysis, postser-
oconversion time lines should be defined consistently and
studies should be explicit in what primary data were
acquired (e.g. diagnosis date, estimated infection date,
estimated seroconversion date). Diagnosis is the most
feasible trigger for postseroconversion follow-up, but
depending on the frequency of testing, diagnosis could
occur at different phases of actual infection, leading to
impacts on analyses of timing of early infection events, for
which estimated infection and seroconversion dates may
be more useful.
Consistent definitions, determinations and uses of
diagnosis, estimated infection, and estimated seroconver-
sion dates will depend on a common frequency of rapidpyright © Lippincott Williams & Wilkins. UnauthoHIV testing and storage of plasma/blood samples across
parent studies. To more accurately estimate dates of
infection and seroconversion, plasma samples or dried
blood spots could be stored from all visits in case HIV
RNA testing is needed at a later date. Such an approach
was taken in FEM-PrEP, which used monthly antibody
testing and collection of plasma, and HVTN 505, which
employed antibody testing and storage of blood samples
less frequently. During protocol development, the cost of
collecting and storing plasma/blood samples for possible
HIV RNA analysis would need to be balanced against the
analytical needs.
Frequent (monthly) HIV testing is advantageous, facil-
itating an accurate estimation of seroconversion and/or
infection dates and collection of samples/assessments at
early time points. Furthermore, although study partici-
pants are counseled to be alert for signs of acute infection
syndrome, few seroconverters are identified by clinical
symptoms [48]. Most seroconverters do experience
clinical symptoms attributable to acute HIV infection,
but they do not always realize or report it [49]. Therefore,
frequent HIV testing also has the advantage of identifying
more participants during acute infection. Also, HIV
testing reduces the potential for prolonged exposure to
incompletely suppressive ART in the face of occult/
undetected acute/primary HIV infection. We found that
HIV antibody testing is usually done on a monthly or
quarterly basis; testing less frequently than monthly not
only complicates estimation of seroconversion date but
could also increase seroconverters’ exposure to suboptimal
treatment regimens. However, the cost and feasibility of
monthly testing must also be considered. The CDC’s
interim guidance for the use of PrEP for prevention of HIV
infection in MSM now calls for testing every 2–3 months
[50] and some upcoming studies, such as HPTN 069 [37],
will use quarterly testing to reduce costs. Although
monthly testing for HIV is costly, new testing technologies
(e.g., combined antibody/antigen tests) might make it
more feasible. Until then, the advantages of frequent HIV
testing must be balanced against its costs and participant
acceptability of such frequent assessments. Protocol teams
might adjust the frequency of HIV testing to the
intervention method. For example, vaccine studies in
which participants are not taking PrEP might test
quarterly; studies in which participants do take PrEP
might reduce risk of prolonged exposure to suboptimal
treatments by using monthly testing.
Although considerable overlap exists among protocols in
regard to sample collections/assessments, variation in
timing complicates comparison across protocols. To more
easily and effectively aggregate and compare findings from
multiple protocols, the SSG makes the recommendations
and provides examples in Table 5. These examples are
based on a hypothetical harmonization of current and
recent protocols. Design of a collaborative rollover
protocol would require careful consideration of the studyrized reproduction of this article is prohibited.
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available resources.
Owing to a low rate of seroconversion inprevention studies
and the need to follow seroconverters long term to address
present research questions, it would be advantageous to
consider cross-sponsor data utilization agreements that
would allow aggregation of data from multiple studies, and
promote data usage by a broad research community.
Aggregation of data can be made possible by a common
seroconverter rollover protocol or protocol design that
includes a core set of study objectives, samples, and
assessments. Common standards for consent and reten-
tion approaches and a core set of objectives, samples and
assessments would require commitment and coordina-
tion across research teams. Study-specific goals could
be accommodated by allowing study teams to include
additional objectives, sample collections, and assessments
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